Vancomycin-resistant enterococcus bloodstream infection successfully managed with oritavancin and fosfomycin as sequential treatment.
Caterina Di CeccoJacopo MonticelliStefano di BellaVittorio Di MasoRoberto LuzzatiPublished in: Journal of chemotherapy (Florence, Italy) (2023)
Bloodstream infections caused by vancomycin-resistant enterococci are increasingly reported and a consensus therapy does not exist. Oritavancin has shown good antimicrobial activity against VRE, but its use is mainly limited to skin, soft tissue, and/or bone infections. Fosfomycin is increasingly used for enterococcal infections (including bloodstream infections and endocarditis) as a partner drug given its anti-biofilm and synergistic properties. Recently in vitro and in vivo synergism between oritavancin and fosfomycin against VRE isolates has been demonstrated. Herein we report the case of a hematologic patient with a VRE bloodstream infection successfully treated with oritavancin and fosfomycin as sequential treatment.
Keyphrases
- gram negative
- soft tissue
- urinary tract infection
- methicillin resistant staphylococcus aureus
- multidrug resistant
- staphylococcus aureus
- pseudomonas aeruginosa
- stem cells
- emergency department
- klebsiella pneumoniae
- candida albicans
- escherichia coli
- human immunodeficiency virus
- cystic fibrosis
- combination therapy
- clinical practice
- replacement therapy
- cancer therapy
- smoking cessation
- drug induced
- genetic diversity
- antiretroviral therapy